On Aug. 20, 2020, GT Biopharma and Cytovance announced a collaboration agreement whereby Cytovance will providing drug development services to assist the GT Biopharma with its TriKEﾙ therapeutic for the treatment of COVID-19 infection.

The TriKEﾙ COVID-19 therapeutic is designed to seek out and kill Novel Coronavirus 2019 virus infected cells before the release of additional virus particles from such infected cells.